1. Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma
- Author
-
Barbara Sarina, Stefania Bramanti, Massimo Magagnoli, Monica Balzarotti, Davide Soligo, Rita Mazza, Elisabetta Todisco, Laura Giordano, Armando Santoro, Franco Aversa, Luca Castagna, Antonella Anastasia, and Andrea Bacigalupo
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Allogeneic transplantation ,Adolescent ,medicine.medical_treatment ,Disease ,Hematopoietic stem cell transplantation ,Human leukocyte antigen ,Disease-Free Survival ,Risk Factors ,Internal medicine ,hemic and lymphatic diseases ,Living Donors ,High-dose chemotherapy ,Medicine ,Humans ,Transplantation, Homologous ,Retrospective Studies ,Transplantation ,Chemotherapy ,business.industry ,Hematology ,Hematopoietic Stem Cells ,Hodgkin Disease ,Radiation therapy ,Survival Rate ,Immunology ,Female ,Salvage chemotherapy ,Stem cell ,business ,Hodgkin lymphoma ,Follow-Up Studies - Abstract
The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.
- Full Text
- View/download PDF